Traphaco Joint Stock Company
HHOSE:TRA36,000.00
VND
0.00
(0.00%)
ISIN
VN000000TRA8
Return %
Stock
S&P 500
1Y
9.09
14.20
3Y
-14.29
81.12
5Y
-18.37
68.34
Capital Structure
VND
•
in mil. unless spec.Working Capital
VND
•
in mil. unless spec.Growth Rates
VND
•
in mil. unless spec.Quarterly Revenue
VND
•
in mil. unless spec.Quarterly Earnings Per Share
VND
•
in mil. unless spec.Quarterly Dividends Per Share
VND
•
in mil. unless spec.Company Description
- CEO
- Ma Tuc Tran
- Full Time Employees
- 1,546
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Ha Noi Vietnam
- IPO Date
- Nov 12, 2008
- Website
- traphaco.com.vn
- Similar Companies
- Business
- Traphaco Joint Stock Company is a Vietnam-based pharmaceutical enterprise primarily engaged in the research, development, manufacture, distribution, and commercialization of traditional herbal medicines, modern chemical pharmaceuticals, dietary supplements, cosmeceuticals, and medical supplies. Founded in 1972 and headquartered in Hanoi, Vietnam, the company operates across over-the-counter (OTC) and prescription hospital tender (ETC) segments, serving domestic healthcare providers, retail pharmacy networks, and international export markets. Traphaco conducts its manufacturing and research operations through specialized subsidiaries and production facilities, including Traphaco CNC Joint Stock Company and Traphaco Hung Yen Company Limited, supported by GACP-WHO certified medicinal plant cultivation areas. The company organizes its commercial operations into three core business divisions: Herbal Pharmaceuticals (Phytomedicines), Modern Pharmaceuticals, and Health Supplements and Personal Care. Its comprehensive product and service portfolio includes: traditional herbal and natural medicines, featuring hepatoprotective agents under the Boganic and Boganic Premium brand names, cerebral circulatory tonics under the Hoat Huyet Duong Nao and Cebraton brands, hemorrhoid remedies under the Totri brand, gastrointestinal treatments under the Ampelop brand, and herbal antitussives under the Methorphan brand; modern chemical pharmaceuticals, comprising cardiovascular therapies, antidiabetic drugs, central nervous system medications, analgesics, antipyretics, antibiotics, and digestive treatments; dietary and health supplements, including nutritional tonics and immune support formulations under the Antot and Antot Thymo brands, as well as vitamin and mineral supplements; personal care and antiseptic solutions, including T-B brand mouthwashes, physiological saline solutions, and ophthalmic drops; and contract manufacturing, quality testing, packaging, warehousing, and nationwide distribution services across a network of tens of thousands of pharmacies and healthcare institutions. In recent developments, Traphaco is executing a dual-engine growth strategy designed to sustain its market-leading position in traditional phytomedicines while rapidly scaling its capabilities in modern Western pharmaceuticals. The company has deepened its strategic alliance and technology transfer cooperation with South Korea-based Daewoong Pharmaceutical and major institutional shareholders, enabling the domestic transfer, technical validation, and manufacturing of advanced prescription formulations across cardiovascular, metabolic, and gastrointestinal therapeutic areas. To support this expansion, Traphaco has upgraded its smart pharmaceutical plant in Hung Yen toward EU-GMP compliance, enhancing production automation and sterile formulation capacity to increase penetration in the hospital prescription channel. Furthermore, the company has expanded its product catalog with high-value functional supplements and premium brand extensions, while optimizing its supply chain and digital sales platforms to improve distribution efficiency across retail and institutional healthcare channels.